Tumor Organoid Co-culture Models

Overview of Tumor Organoid Co-culture Models

Conventional tumor organoids generally do not contain the essential cellular constituents of TME. Tumor organoid co-culture models aim to fill this gap by systematically integrating autologous or allogenic non-malignant cells, such as cancer-associated fibroblasts (CAFs), different immune cell subtypes (e.g., T cells, NK cells, macrophages), endothelial cells, and neural cells, with tumor organoids. This combination generates a more holistic in vitro model fulfilling several requirements, including presentation of crosstalk between tumor and stroma, immune evasion systems, angiogenesis machinery, and metabolic interactions, which represents a higher level for the research of the entire process of cancer progression with metastasis development and therapy response.

Different co-culture approaches have been devised for distinct goals like studying intercellular communication, immune therapy, and patient-tailored cytotoxicity. The most common technique consists of isolating and expanding epithelial tumor cells from tissues and co-culturing with CAFs, tumor-infiltrating lymphocytes (TILs), or peripheral blood mononuclear cells (PBMCs) in pairs, triplicates, or even higher combinations.

Key Capabilities and Applications of Tumor Organoid Co-culture Models

Our Services

Leveraging deep expertise in 3D cell culture, TME biology, and customized assay development, we offer end-to-end tumor organoid co-culture model services. Our strength lies in tailoring each model's cellular composition, culture conditions, and validation endpoints to directly address your specific research questions, from validating a novel target's role in immune suppression to profiling specific responses to combination therapies.

Types of Tumor Organoid Co-culture Models

To model the complex TME, we provide a diverse portfolio of advanced co-culture systems, categorized by cellular composition and methodological platform. These models are designed to isolate and study critical biological interactions, from immune surveillance and stromal remodeling to vascular recruitment and microbial influence. By selecting and combining these specialized systems, researchers can build increasingly complete in vitro representations of human cancer biology, tailored for specific mechanistic or therapeutic investigations.

Customized Solutions for Tumor Organoid Co-culture Models

• Project Consultation & Design: Collaborative design of the co-culture system based on research objectives, including selection of appropriate cell sources (patient-derived or commercial), ratios, and culture matrices.
• Protocol Development & Optimization: Establishment and rigorous optimization of robust protocols for co-culture establishment, maintenance, and medium formulation to ensure viability and functionality of all cell types.
• Functional Validation & Characterization: Comprehensive analysis including viability assays, cytokine/chemokine profiling, immunohistochemistry/immunofluorescence for spatial analysis, and flow cytometry for cellular composition.
• Therapeutic Testing & Analysis: Customized endpoint assays for drug screening, immune cell-mediated killing, invasion/migration, and downstream molecular analysis (e.g., RNA-seq from specific sorted cell populations).
• Data Analysis & Reporting: Provision of detailed, interpretative reports with high-quality data visualizations and biological insights.

Research Services for Tumor Organoid Co-culture Models

Alfa Cytology's expertise provides a complete, integrated research service based on tumor organoid co-culture models, supporting both fundamental discovery and translational development. For basic research, we facilitate the investigation of tumor-immune cell crosstalk, immune evasion mechanisms, and TME biology. In preclinical and translational research, our models are applied to evaluate novel therapeutic agents, perform toxicity assessments, validate new targets, and generate robust efficacy data to support investigational new drug applications.

Case Study - Colorectal Cancer Organoid Co-Culture Model Development

Alfa Cytology developed an advanced colorectal cancer organoid-CAF co-culture model to address the critical limitation of missing stromal interactions in standard organoid cultures. A sequential co-culture protocol was established, where colorectal cancer organoids were first embedded within a biologically relevant hydrogel matrix. Subsequently, CAFs were introduced into the culture in a defined ratio. This method was optimized to maintain the viability and proliferation of both cell types in a shared medium formulation without specialized growth factor supplementation. The model effectively recapitulated key in vivo interactions, with CAFs supporting organoid growth and restoring signaling pathways absent in monoculture. Functional validation confirmed the system's reliability for evaluating standard-of-care chemotherapeutic agents, demonstrating its utility for predictive drug response studies and customized therapy applications.

Fig.1 A sequential co-culture method for CRC organoids and CAFs supports robust organoid growth. (A) Growth of CRC organoids cultured with or without CAFs. (B) Growth of CRC organoids under three conditions: co-cultured with CAFs, cultured alone in standard medium (containing EGF and FGF), or cultured alone in reduced medium without medium supplements. Data are presented as mean ± SEM (n=5; *p < 0.05).

Contact Us

Alfa Cytology is committed to providing scientifically rigorous, customizable, and data-driven tumor organoid co-culture model services to accelerate your oncology research and drug development pipeline. To discuss how our tailored co-culture solutions can advance your specific project, please get in touch with our scientific team for a detailed consultation.

For research use only.